Is the business good?
How good a business is LNTH?
Lantheus Holdings, Inc. earns 18% on the capital it employs against a 9.0% cost of capital, so the business is worth more the bigger it gets.
18%
Return on invested capital · cost of capital 9.0% · 8.8 points above what the capital costs: growth creates value
- Operating margin
- 19%
Operating margin · Drug Manufacturers - Specialty & Generic median 12% · 12 months to Q1 2026
- Cash conversion
- 1.35×
Cash conversion · 1.86× a year ago · every dollar of reported profit arrived as cash, and more
- Share count, year on year
- −8.0%
Share count, year on year · bought back, each share owns more of the company
| Year | Operating margin |
|---|---|
| FY2020 | −1.2% |
| FY2021 | −14% |
| FY2022 | 3.9% |
| FY2023 | 28% |
| FY2024 | 30% |
| FY2025 | 20% |
Details›
- Gross margin12 months to Q1 2026
- 60%
- Operating margin12 months to Q1 2026
- 19%
- Net margin12 months to Q1 2026
- 18%
- Free cash flow margin
- 24%
- R&D as % of revenue
- 12%
- Revenue, trailing twelve months
- $1.55B
- Free cash flow, trailing twelve months
- $377M
- Net income, trailing twelve months
- $279M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 18%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Drug Manufacturers - Specialty & Generic
Ranks #25 of 28 by Smart Score